Besifloxacin hydrochloride 405165-61-9

Focusing on innovative research, development, and production in the field of fine chemicals, we prioritize technology, quality, and market orientation. We collaborate with global partners to build a high-tech chemical industry chain and promote sustainable development in the industry.

The company's main products include pharmaceutical intermediates, food additives, essence, spices and plant extracts. The products have passed international certification and are exported to Europe, America, Japan, South Korea and Southeast Asia.

Besifloxacin hydrochloride Basic information

Outline Besifloxacin hydrochloride ophthalmic suspension

Product Name:	Besifloxacin hydrochloride
Synonyms:	(R)-7-(3-AMinohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid HCl;3-Quinolinecarboxylic acid, 7-[(3R)-3-aMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI);(R)-7-(3-aMinoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride;Besifloxacin HCl;Unii-7506A6J57t;(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride;Besifloxacin hydrochloride;Besifloxacin HC
CAS:	405165-61-9
MF:	C19H22Cl2FN3O3
MW:	430.3
EINECS:	696-612-6
Product Categories:	API;Inhibitors;Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	405165-61-9.mol

Besifloxacin hydrochloride Chemical Properties

Melting point	>210°C (dec.)
storage temp.	Inert atmosphere,2-8°C
solubility	Methanol (Slightly, Heated, Sonicated), Water (Slightly, Heated, Sonicated)
form	Solid
color	Off-White to Light Beige
InChI	InChI=1/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/s3
InChIKey	PMQBICKXAAKXAY-MEQOOBBNNA-N
SMILES	ClC1C(N2CCCC[C@@H](N)C2)=C(F)C=C2C(=O)C(C(=O)O)=CN(C3CC3)C=12.Cl |&1:8,r|

Safety Information

Besifloxacin hydrochloride Usage And Synthesis

Outline	Besifloxacin hydrochloride is developed by Bausch & Lomba as a new type of fluoroquinolones for the treatment of bacterial conjunctivitis (a non-viral caused infectious purulent eye irritation conjunctivitis ). Bacterial conjunctivitis which is a contagious eye disease, is a common disease that affects people of all ages. The clinical symptoms of infested eye including: foreign body sensation, burning sensation, tearing; conjunctival hyperemia, mucus or purulent discharge; eyelid edema, conjunctival edema and subconjunctival hemorrhage may occur in severe cases .
Besifloxacin hydrochloride ophthalmic suspension	Besifloxacin hydrochloride ophthalmic suspension (Besivance) is a fluoroquinolone drug recently approved for the topical treatment of bacterial conjunctivitis. This medicine can quickly kill common pathogens causing conjunctivitis , that is coagulase-negative staphylococci, Streptococcus pneumoniae, Staphylococcus aureus , Haemophilus influenzae bacteria, and other less common bacteria.. Besifloxacin is an effective drug to the Gram-positive and Gram-negative pathogens, include other fluoroquinolone-resistant bacteria , also it can balance the DNA gyrase and topoisomerase IV activity, slow the development of resistance. Topical administration can achieve stable and lasting high concentrations in human tears , and penetration in animal ocular tissue is good, showing excellent safety. Pharmacokinetic and pharmacodynamic characteristics of Besifloxacin meet the criteria for successfully clearing most Gram-positive and Gram-negative bacteria, while exhibiting minimal systemic exposure.Besifloxacin biochemical properties, pharmacokinetics targeted to achieve/pharmacodynamic objectives and limited to local ophthalmic drug will slow the development of bacterial resistance, making Besifloxacin become attractive choice for acute bacterial conjunctivitis treatment. The above information is edited by the chemicalbook of Tian Ye.
Description	Besifloxacin is a new fluoroquinolone antibacterial for ophthalmic use. It is indicated for the treatment of bacterial conjunctivitis, one of the most common ocular infections encountered in the primary care setting. Although the previously marketed fluoroquinolones ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, and moxifloxacin have been widely used to treat bacterial conjunctivitis, their continued utility is hampered by the emergence of resistance among key ocular isolates such as Staphylococcus aureus. Besifloxacin is the first fluoroquinolone developed exclusively for topical ophthalmic use. Unlike the previously marketed fluoroquinolones, besifloxacin has not been used systemically and is not in development as a systemic agent. Its exclusive indication as a topical agent is expected to reduce the overall environmental exposure of bacteria to besifloxacin, which may contribute to a lower risk for the emergence of bacterial resistance. Fluoroquinolones derive their antibacterial activity via inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which regulate processes of DNA replication. Besifloxacin inhibits DNA gyrase and topoisomerase IV from Streptococcus pneumoniae (IC50 = 1 and 0.4 mg/ L, respectively) and Escherichia coli (IC50 = 1 and 10 mg/L, respectively).
Chemical Properties	Pale Yellow Solid
Originator	SSP Co. Ltd. (Japan) (Japan)
Uses	Besifloxacin HCl is a fourth-generation fluoroquinolone antibiotic
Uses	A Fluoroquinolone antibiotic.
Brand name	Besivance
Side effects	The most common adverse event reported in patients treated with besifloxacin ophthalmic suspension was conjunctival redness. Other less common adverse events were blurred vision, eye pain, eye irritation, eye pruritus, and headache.
Synthesis	Besifloxacin is a fourth-generation fluoroquinolone antibiotic which is marketed as besifloxacin hydrochloride. It was originally developed by the Japanese firm SSP Co. Ltd and designated SS734. SSP then licensed U.S. and European rights of SS734 for ophthalmic use to InSite Vision, Inc., in 2000, who then developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003. The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009 and marketed under the trade name Besivance. Besifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro. The synthesis of besifloxacin commences with commercially available ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate.Condensation of this ketoester with triethyl orthoformate resulted in a mixture of vinylogous esters 14. Substitution with cyclopropanamine converts 14 to the vinylogous amide 15 as an unreported distribution of cis- and trans-isomers. This mixture was treated with base at elevated temperature to give 16. Presumably, the trans-isomer isomerizes to the cis-isomer, which subsequently undergoes an intramolecular nucleophilic aromatic substitution with concomitant saponification to construct quinolone acid 16. Quinolone 16 is then subjected to another nucleophilic substitution involving readily available iminoazepine 17 and the displacement reaction proceeds regioselectively to furnish the atomic framework of besifloxacin (18). Acidic methanolysis of 18 at elevated temperature gave besiflozacin (III).



——  Q&A  ——

Q1:Do you provide sample?

A: Yes, we can provide free sample, you only need pay the shipping cost.

Q2: What is the lead time?

A: For stock goods, it usually take about 5-7 days by air, 15-30 days by sea,For customized products, the delivery time needs to be confirmed based on the actual situation.

Q3: How can I buy? What is the payment method?

A: You can contract us through Email or you can browse our website:orientchem.cc, we have bank transfer,

A：We attach great importance to after-sales service of our products. If there are any quality issues, please contact us within 30 days of receiving the goods and we will handle returns and exchanges for you.